



Published in final edited form as:

Am J Reprod Immunol. 2010 August 1; 64(2): 113–125. doi:10.1111/j.1600-0897.2010.00823.x.

Maternal Death Following Cardiopulmonary Collapse after Delivery: Amniotic Fluid Embolism or Septic Shock Due to Intrauterine Infection?

Roberto Romero, MD^{1,2}, Nicholas Kadar, MD, JD, Edi Vaisbuch, MD^{1,3}, and Sonia S. Hassan, MD^{1,3}

¹ Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland and Detroit, MI, USA

² Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA and Hutzel Women's Hospital, Detroit Medical Center, Detroit, MI, USA

³ Wayne State University School of Medicine, Department of Obstetrics and Gynecology, Detroit, MI, USA

Abstract

Problem—The amniotic fluid embolism (AFE) syndrome is a catastrophic complication of pregnancy frequently associated with maternal death. The causes and mechanisms of disease responsible for this syndrome remain elusive.

Methods of study—We report two cases of maternal deaths attributed to AFE: 1) one woman presented with spontaneous labor at term, developed intrapartum fever, and after delivery had sudden cardiovascular collapse and disseminated intravascular coagulation(DIC), leading to death; 2) another woman presented with preterm labor and foul-smelling amniotic fluid, underwent a Cesarean section for fetal distress, and also had postpartum cardiovascular collapse and DIC, leading to death.

Results—Of major importance is that in both cases, the maternal plasma concentration of tumor necrosis factor (TNF)- α at the time of admission to the hospital and when patients had no clinical evidence of infection was in the lethal range (a lethal range is considered to be above 0.1 ng/mL).

Conclusions—We propose that subclinical intra-amniotic infection may be a cause of postpartum cardiovascular collapse and DIC and resemble AFE. Thus, some patients with the clinical diagnosis of AFE may have infection/systemic inflammation as a mechanism of disease. These observations have implications for the understanding of the mechanisms of disease of patients who develop cardiovascular collapse and DIC, frequently attributed to AFE. It may be possible to identify a subset of patients who have biochemical and immunological evidence of systemic inflammation at the time of admission, and before a catastrophic event occurs.

Keywords

Bacteremia; cardiorespiratory arrest; chorioamnionitis; disseminated intravascular coagulation; DIC; fever; intra-amniotic infection; pregnancy; preterm labor; tumor necrosis factor- α

INTRODUCTION

The differential diagnosis of sudden cardiovascular collapse and disseminated intravascular coagulation (DIC) in pregnant women is a clinical challenge. This condition may occur during pregnancy or in the immediate postpartum period, and is often attributed to amniotic fluid embolism (AFE); yet, the status of AFE as a distinct entity has been debatable.^{1;2} This condition has been proposed to be a syndrome¹ caused by multiple etiologies, such as an “anaphylactoid-like reaction”,^{3;4} emboli of particulate material from amniotic fluid,^{5–7} and sepsis.²

We report herein two cases of maternal death following cardiopulmonary collapse after delivery. These cases are of interest for three reasons. First, both cases were associated with intrauterine infection and with plasma tumor necrosis factor (TNF)- α concentrations, which were considered to be above the lethal range.⁸ Host derangements during sepsis that lead to shock, multi-system organ failure, and DIC are known to be caused by endogenous mediators produced by cells of the immune system in response to overwhelming infection.⁹ However, subclinical intrauterine infections are not known to trigger similar host responses during pregnancy.

Second, at the time of the cardiopulmonary collapse, the clinical diagnosis in one patient was AFE, which was also part of the differential diagnosis in the second patient. Since subclinical intrauterine infection is not widely recognized as a cause of cardiopulmonary collapse and DIC, cases of subclinical intrauterine infection may be misdiagnosed as AFE² and, hence, inadequately treated.

Third, the hemodynamic changes in these patients were similar to those previously reported in some patients with AFE.^{1;9–20} The parallels of the clinical and hemodynamic picture caused by subclinical intrauterine infection and AFE suggest that the same mediators^{21–24} maybe implicated in the host response of these conditions.

These two cases came to our attention because they occurred during a short period of time and resulted in maternal death.

CASE REPORTS

Case 1

A 29-year old gravida 3, para 1 was admitted in early labor at 41 5/7 weeks' gestation. On examination, thick meconium and fetal heart rate decelerations were noted. As preparations were being made for a Cesarean delivery, the fetal heart tracing improved, an amnioinfusion was administered and the patient was allowed to continue to labor. Augmentation with oxytocin was undertaken, and an intrauterine pressure catheter was placed two hours after augmentation began. Twelve hours after admission, at a cervical dilatation of 8 centimeters, an epidural was administered. Forty minutes after the epidural was given, the patient had a temperature of 38.7°C, and blood cultures were drawn. The temperature rose to 39.2°C twenty minutes later. Shortly thereafter, the patient became fully dilated, and the fetus was delivered by vacuum extraction at 10:10 pm because of fetal heart rate decelerations. The placenta was delivered intact two minutes later.

Immediately after delivery, the patient developed a clinically progressive coagulopathy. Uterine bleeding persisted despite multiple injections of methergine and carboprost, and she began to bleed from intravenous sites and small, first degree vaginal lacerations. Within an hour after delivery, the patient developed hypotension (blood pressure 88/56), tachycardia (pulse 162), tachypnea (respiratory rate 44/min), and blood in a red top tube did not clot. At

this time, the patient's hemoglobin (Hgb) was 9.8 g/dl, white blood cell(WBC) count was 6,600 cells/ μ L, and the platelet count was 115,000/mL. The bleeding from the intravenous sites became profuse. Transfusions were begun at 11:40 p.m. and by midnight, the patient had received 4 units of packed red blood cells (PRBCs) and 4 units of fresh frozen plasma (FFP). Half-an-hour later the patient was intubated because of progressive respiratory failure. An arterial blood sample showed a pH 7.05, PaO₂ 487 mmHg, PaCO₂ 37 mmHg, and HCO₃⁻ 10 mEq/L. The patient continued to be hypotensive and was started on norepinephrine and dopamine. At 2:00 a.m. (i.e., about four hours after delivery and three hours after cardio-respiratory symptoms began), the patient developed pulmonary edema confirmed by chest X-ray and furosemide was administered. A coagulation profile showed: a fibrinogen 107 g/L, a prolonged prothrombin time (PT) 18.7 secs, and an activated partial thromboplastin time (aPTT) 123 secs. The Hgb was 9.0 g/dl and the hemorrhage was abating. The patient had received 24 units of PRBCs, 23 units of FFP, 3 units of platelets, and 2 units of cryoprecipitate. The antepartum blood cultures were reported to contain Gram positive cocci growing in pairs, and the patient was started on broad-spectrum antibiotics (ampicillin, gentamicin and clindamycin). Subsequently, the patient received metronidazole and was given intravenous hydrocortisone. Because of persistent hypotension and pulmonary edema, a Swan-Ganz catheter was placed at 4:00 a.m. Right and left heart pressures were as follows: the right arterial pressure (RAP) was 25 mmHg, pulmonary artery pressure (PAP) 35/25 mmHg, and pulmonary capillary wedge pressure (PCWP) 25 mmHg. The cardiac output was 2.3 L/min. Two hours later the chest X-ray had improved with continued diuresis. Over the next twelve hours, the patient remained hypotensive despite vasopressor and inotropic support, and had a cardiac arrest which was refractory to all resuscitative efforts. The patient was pronounced dead 19 hours after delivery. An autopsy was declined by the family. Placental histology revealed acute chorioamnionitis.

After the death of the patient, samples of blood which had been drawn for clinical care were retrieved for cytokine analysis. The blood sample had been collected at admission as part of routine care to determine a complete blood count (CBC, lavender tube collected with EDTA). Plasma TNF- α was assayed using a commercially available enzyme-linked immunosorbent assay (ELISA) (Factor Test-Human TNF- α , Genzyme Corporation, Cambridge, MA, USA). The plasma TNF- α concentration was 1 nanogram per ml.

Case 2

A 30-year old gravida 3, para 2 was admitted in premature labor at 28 2/7 weeks' gestation. The patient had a history of asthma, two prior cesarean sections, and was allergic to erythromycin. There was no evidence of rupture of membranes (nitrazine, ferning, and pooling were negative), and the cervical dilatation was 4 centimeters with bulging membranes. The patient received two doses of Betamethasone (12 mg intramuscularly) and tocolysis with magnesium sulfate and indomethacin, which was only temporarily effective, as spontaneous rupture of membranes occurred 24 hours after admission. The amniotic fluid was foul-smelling, but the patient remained afebrile; 31.5 hours after admission the patient was delivered by Cesarean delivery under spinal anesthesia, due to a non-reassuring fetal heart tracing. Blood cultures were performed prior to delivery, and placenta, uterus and cord blood were cultured after delivery of the neonate. Cultures from the uterus were positive for *Bacteroides bivius* but the other cultures were negative. Histology of the placenta showed chorioamnionitis, funisitis and chorionic vasculitis.

In the recovery room, the patient complained of shortness of breath. The dressing over the incision was saturated with blood and vaginal bleeding was noted. The patient developed tachycardia (pulse 150) and hypotension (blood pressure 80/50). Oxygen saturation was 75% by pulse oximetry, and arterial blood gases (the patient was receiving 10 L/min of O₂ by face mask) were: pH 7.22; PaO₂ 74 mmHg; PaCO₂ 30 mmHg; HCO₃⁻ 12 mEq/L; %Sat

O₂ 92%. Shortly afterwards the patient had a cardio-respiratory arrest. She was immediately intubated and ventilated and was successfully resuscitated. A Swan-Ganz catheter and aortic line were placed to monitor hemodynamic status.

After resuscitation, coarse rhonchi and expiratory wheezing were heard over both lungs. Chest X-rays obtained immediately before and after resuscitation showed ground glass opacities suggestive of early acute respiratory distress syndrome (ARDS). Immediately after resuscitation, arterial blood gases on 100% inspired O₂ were: pH 7.10; PaO₂ 128 mmHg; PaCO₂ 37 mmHg; HCO₃⁻ 10 mEq/L; %Sat O₂ 97%. Initial central pressures were: mean RAP 15 mmHg, right ventricular pressure 34/6 mmHg, PAP 34/20 mmHg, PCWP 19 mmHg. The patient developed DIC, and became febrile and leukopenic. She received 8 units of PRBCs and 4 units of FFP. CBC and the coagulation profile showed: Hgb 8.1 g/dl, WBC count 2,600 cells/μL, platelet count 144,000/mL, PT 16.3 secs, aPTT 79.2 secs, fibrinogen 243 g/L, and fibrin split products >40 μg/mL.

Following resuscitation, diuresis, and inotropic support, the patient's pulmonary edema resolved and over the ensuing week her post-operative course was characterized by progressive sepsis, leukocytosis, thrombocytopenia and coagulopathy, hypotension and a hyperdynamic state. Blood cultures were positive for Gram positive cocci and *Candida*. The patient developed acute tubular necrosis, hepatic failure and hepatic encephalopathy. Ventilatory support with positive end-expiratory pressure (PEEP), dialysis, hemodynamic monitoring, and vigorous antibiotic therapy was continued and after one week, the patient's condition appeared to be improving. However, the improvement was short-lived and by the end of the second week of hospitalization the patient's temperature and WBC count began to rise. Signs of early pulmonary edema reappeared and the patient required increasingly higher levels of PEEP and FiO₂ to maintain oxygenation. The patient died 17 days after delivery following cardiac arrest and electromechanical dissociation that was refractory to all resuscitative measures.

A plasma sample for CBC had been obtained 24 hours after admission when the membranes ruptured spontaneously and 7.5 hours prior to delivery. This sample was assayed for TNF-α as previously described and the concentration was 10 nanograms per ml.

Review of records of these two cases was approved by the Human Investigations Committee of Wayne State University, since the faculty of the School of Medicine covered the obstetrical service at Hutzel Hospital, Detroit, Michigan, where the patients were treated.

DISCUSSION

Principal findings

1) Two pregnant women developed cardiovascular collapse and DIC in the immediate postpartum period and eventually died. The differential diagnosis included AFE; 2) both patients had been admitted without evidence of infection or systemic inflammation. One developed an intrapartum fever after epidural anesthesia, while the other patient was afebrile but had preterm labor with foul-smelling amniotic fluid. Both patients had positive cultures for microorganisms (blood in one case and uterine in the other) and had histologic evidence of chorioamnionitis; 3) blood samples that had been obtained hours before cardiovascular collapse and DIC showed plasma concentrations of TNF-α 10 and 100 times above the lethal concentration in meningococcal sepsis; yet, the mothers were asymptomatic; 4) we propose that infection can cause a clinical picture similar to AFE, and that some cases of AFE may be due to this cause; 5) determination of cytokines at the time of admission to the hospital may help identify pregnant women at risk for cardiovascular collapse and DIC before the clinical manifestations of these complications.

The description of amniotic fluid embolism as a unique complication of pregnancy

Although a case of AFE (maternal death in a case of stillbirth with embolic material in the lungs) was reported in 1926 by Meyer⁵ in Sao Paulo, Brazil, this case published in Portuguese went unrecognized for many years. The credit for a systematic description of AFE has been attributed to Steiner and Lushbaugh in 1941 in a classic paper entitled “Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics”.⁶ The authors described 8 women who died of this condition. They considered that the striking and essential pathological findings were emboli of foreign bodies (fetal material) in the blood vessels of the maternal lung. The control group consisted of 34 women who died during labor or within the first 7 days of delivery, and whose clinical presentation was not consistent with AFE. None of the 34 mothers had the embolic material in the lungs.⁶

Steiner and Lushbaugh⁶ also provided experimental evidence that intravenous injection of human amniotic fluid rich in vernix or meconium into dogs and rabbits could cause a similar clinical condition as the one described in humans in the same paper. On the basis of the clinical presentation, detailed pathologic examination and experimental studies, Steiner and Lushbaugh proposed a new obstetrical disease: AFE. The association between AFE and DIC was reported in 1950 by Weiner and Reid.²⁵

There has been reluctance over the years to accept AFE as a disorder because of unanswered questions about the etiology and the mechanism of disease.¹ For example, the amount of amniotic fluid debris present in the lungs has been considered insufficient by some to explain death on a mechanical basis alone.^{1;26} Others found difficulty in accepting the alternative explanation favored by Steiner and Lushbaugh⁷ that an “anaphylactoid-like reaction” could be responsible for the disorder. There has also been the concern that AFE could be a convenient diagnosis to attribute unexplained, sudden obstetrical death caused by other conditions such as cardiac arrest or anesthesia-related death.¹ A controversial issue has been the interpretation of experiments in which amniotic fluid has been injected into animals.¹ Several investigators have reported conflicting results. In some experiments, animals have developed a syndrome similar to AFE,^{27–31} while in others, the syndrome did not develop at all.^{32;33}

Current understanding of amniotic fluid embolism

AFE typically occurs during labor and delivery or in the immediate postpartum period, although it can occur as late as 48 hours postpartum. About 70% of cases (range, 63–76%) occur before delivery and the rest in the immediate postpartum period. A minority of AFE cases occur before labor (13%). Indeed, AFE has been reported to occur following induced abortion, feticide, transabdominal amniocentesis, blunt abdominal trauma, surgical trauma and removal of a cervical suture.²⁰

AFE is considered a syndrome that resembles anaphylactic and septic shock and it has been proposed that the mediators are released in response to fetal antigens.^{1;2} This interpretation is based on the observations by Clark et al² who reported the findings collected by the National Registry of cases of AFE as well as the experimental evidence of several investigators.^{3;4;34;35} The reader is referred to a recent review of AFE.²⁰

Sepsis and septic shock: complex phenotypes with different molecular pathophysiology

Severe sepsis is the leading cause of death in intensive care units, and accounts for 9.3% of all deaths in the United States per year.^{36–39} Indeed, sepsis is the third leading cause of death in developed societies with mortality comparable to myocardial infarction.^{37;39} It is defined by the clinical signs of a systemic inflammatory response to infection.^{40;41} A

diagnosis requires evidence of bacterial infection and at least two of the following signs: 1) abnormalities of body temperature (fever or hypothermia); 2) tachycardia; 3) tachypnea; or 4) changes in the WBC count (leukocytosis or leukopenia). If the clinical process is associated with signs of organ dysfunction, sepsis is considered severe. Examples of these signs are hypoxemia, oliguria, elevated liver enzymes, lactic acidosis or altered cerebral function.^{40;41} The disappointing results of clinical trials to treat sepsis have led to the realization that there is substantial phenotypic heterogeneity in this condition. Indeed, treatment with recombinant human activated protein C has been approved by the FDA only for a subset of patients with sepsis.⁴² Therefore, several leaders in the field have proposed that a distinction be made between septic shock and sepsis. Septic shock refers to a highly lethal syndrome of cardiovascular collapse that results in death within 24–48 hours after onset. It has been noted that most cases of sepsis show a more protracted clinical course in which there is multiple organ dysfunction leading to death within 7–14 days in 30–70% of the cases.^{43;44} These two clinical syndromes may represent different stages of the progression of sepsis, as is the case in fulminant meningococemia. This is important because there is an increasing realization that these syndromes are distinct disorders and represent different pathophysiologic states. The cytokine profile is different for septic shock and severe sepsis. TNF- α is the prototypic cytokine elevated in septic shock. In contrast, HMGB-1 is the typical cytokine elevated in the course of sepsis.

Intra-amniotic infection is frequent and subclinical

There is a large body of evidence that indicates that microbial invasion of the amniotic cavity is common in women with spontaneous labor at term (the rate of positive culture is 18%), prelabor rupture of membranes at term (32%), preterm labor with intact membranes (13%), preterm PROM (32%), and cervical insufficiency (50%).⁴⁵ The use of molecular microbiologic techniques suggests that the frequency of microbial invasion may be higher than is recognized now.^{46–51} However, most of the cases are subclinical in nature, and diagnosis depends upon the analysis of amniotic fluid. Even in cases of clinical chorioamnionitis (defined as originally proposed by Gibbs et al⁵²), sepsis and DIC are rare. It seems that the immune system and treatment with antibiotics are able to successfully control most infections. An interesting finding of the 2 cases we report is that cardiovascular collapse and DIC occurred after delivery in patients who did not have overt clinical evidence of infection at admission to the hospital, but had TNF- α concentrations that were in the lethal range at that time.

The role of TNF- α in sepsis

TNF- α is a primary mediator of the innate immune response to microbial invasion.⁵³ At low concentrations, TNF- α has been proposed to play a physiological role in maintaining homeostasis.⁵⁴ This cytokine promotes remodeling or replacement of injured or senescent tissue by stimulating fibroblast growth.⁵⁴ However, TNF- α is produced in large amounts in response to microbial products, such as endotoxin and other exogenous and endogenous factors from bacteria, viruses, and parasites.

TNF- α is a sufficient and necessary mediator of septic shock.⁵³ Evidence in support of this is that: 1) this cytokine produces a condition indistinguishable from septic shock when injected into animals,^{55–58} 2) TNF- α is elevated in patients with septic shock;^{8;56–60} and 3) the neutralization of TNF- α can prevent endotoxic or bacteremic shock, even when endotoxins and bacteremia are present in the circulation.⁵⁵ TNF- α is not a mediator of severe sepsis, as defined in the previous section. This is supported by the following observations: 1) TNF- α is almost undetectable in patients with severe sepsis;^{61;62} 2) TNF-deficient knock-out mice can develop sepsis when treated with high doses of endotoxin;⁶³ 3) peak TNF- α production during sepsis correlates with the development of septic shock, but

not with the slow progression of severe sepsis;^{56;57} 4) death from severe sepsis occurs days after TNF- α concentrations have decreased;⁵³ and 5) antibodies against TNF- α are either ineffective or worsen the outcome of peritonitis-induced sepsis in animals.^{64;65} Thus, TNF- α participates in the initial stages of the response to infection and the generation of septic shock, but not in the progression of sepsis to death.

Given the central role of TNF- α in the inflammatory response, blocking its production or action has been widely investigated as a therapeutic strategy in conditions associated with exaggerated inflammatory response and especially in sepsis. However, randomized clinical trials of selective neutralizing antibodies against TNF- α in human subjects with sepsis did not show a significant reduction in mortality; yet, these studies included a highly heterogeneous population.⁶⁶ Nevertheless, anti-TNF- α agents are effective and in use in rheumatoid arthritis and other inflammatory diseases such as psoriasis and ankylosing spondylitis, as well as in cancer.^{66;67} Recently, TNF- α inhibitors have been shown to improve pregnancy rates in women undergoing IVF and to improve birth rates in patients with recurrent spontaneous abortions.^{68–71} The safety of such treatment during pregnancy is not clear.^{72–75}

Several pharmacological approaches have been used to develop agents that block or modify the function TNF- α as a central regulator of inflammation, including monoclonal antibodies, soluble receptors that can bind TNF- α , and small molecules that target specific signaling and synthesis pathways for TNF- α . The different types of anti- TNF- α agents are a subject of a recent review.⁶⁶

TNF- α circulating concentrations

Waage et al.⁹ reported that in patients with meningococcal septicemia, death occurred if the TNF serum concentrations were more than 0.1 ng/mL. Subsequent studies have demonstrated that the elevation of TNF- α is short-lived,^{55;59;76;77} and that the concentrations of this cytokine over time correlate inversely with survival.⁷⁸ However, some patients with TNF- α concentrations in the “lethal range” have survived.⁷⁹

In the two patients presented herein, plasma TNF- α concentrations were 10–100 fold higher than the concentration previously reported to be lethal in patients who have meningococcal septicemia.⁹ Even more astonishing was that these concentrations of TNF- α were present in both women when the intra-amniotic infection was subclinical. High TNF- α serum concentrations have also been reported in patients with shock, which was not caused by demonstrable infection.⁷⁹

There was no evidence of infection when the first patient was admitted in early labor while her TNF- α concentration was 1 ng/mL. Even the clinical manifestations of fever that developed 12 hours later (temperature elevations to 38.7°C and 39.2°C following an epidural in association with a normal WBC count) were tenuous at best. Yet, remarkably enough, this patient already carried a marker for the lethal catastrophe that was to befall her 14 hours later.

The second patient had a TNF- α concentration of 10 ng/mL, 100 times higher than the previously considered lethal concentration;⁹ yet, the only clinical evidence of infection was premature labor refractory to tocolysis.⁸⁰ This patient was suspected to have infection because of the combination of preterm labor and foul-smelling amniotic fluid.

TNF- α concentrations in this high lethal range have been described without shock in patients with leprosy and Ethiopian cutaneous leishmaniasis, which are intracellular infections characterized by a massive pathogenic load.⁸¹ It has been suggested that patients who

tolerate such high doses of TNF- α have circulating inhibitors of TNF- α that neutralize its biological activity.⁸² Without such inhibitors, TNF- α induces severe side effects in patients, including hypotension. For example, in patients with cancer given TNF- α infusions to treat their malignancies, the maximal dose of TNF- α tolerated is limited by side effects and associated with undetectable serum TNF- α concentrations.⁸³

Several studies reported the maternal circulating TNF- α concentrations during normal pregnancy.^{84–97} In a recent study,⁹³ comparing 57 pregnant Finnish women throughout gestation and 62 control women matched for age and smoking, there were no differences in the median TNF- α concentrations in non-pregnant and pregnant women. Furthermore, the median TNF- α concentration in maternal serum did not differ significantly among the three trimesters, with a median (min-max) concentration of 2.28 pg/mL⁻¹ (1.28–5.4) during the third trimester. Similar findings with a lack of change in TNF- α concentration during pregnancy compared to the non-pregnant state^{88;96} and with advancing gestational age^{85;89} were reported by other investigators.

A few studies have addressed the question whether TNF- α concentration in maternal circulation changes during normal labor at term.^{84;85;87;90} Consistently, these studies reported no change in TNF- α concentration in term labor.^{84;85} Conflicting results, however, exist regarding changes in the context of preterm labor,^{84;88;90} with only one study reporting significantly higher median concentration of TNF- α in patients with preterm labor than in controls.

Importantly, among all of these studies, the highest TNF- α concentration reported was in the range of 200–300 pg/ml.^{88;95} In none of these studies did the concentration reach the range of 1 ng/mL.

Amniotic fluid embolism or septic shock?

AFE was the clinical diagnosis in the first patient and part of the differential diagnosis in the second patient. The hemodynamic parameters first recorded after the onset of cardiopulmonary collapse in these patients (Table 1) were similar to those previously reported in patients with AFE.^{1;9–20} We cannot discount the possibility that both patients had two pathological processes, one that caused their cardiopulmonary collapse (AFE) and another totally unconnected with it (sepsis). Autopsies were not performed at the request of the families.

Review of previously published case reports in which clinical findings were reported revealed that less than 10% of women in whom AFE was confirmed by autopsy had fever during labor or the puerperium prior to the onset of symptoms.^{6;7;98–119} These patients invariably had prolonged rupture of the membranes or prolonged labor, suggesting that the infections were secondary and not present at the onset of labor. Moreover, in our patients TNF- α was elevated many hours before the onset of cardio-respiratory symptoms and DIC. For these changes to have been caused by AFE, embolization would have to have preceded the onset of symptoms by hours; however, this has never been observed in animal models of AFE.^{6;28;98;120;121}

These findings have potentially far-reaching diagnostic and management^{70;71;73;122;123} implications. First, by measuring plasma TNF- α and perhaps other cytokines/chemokines/inflammatory mediators, it may be possible to identify those patients at risk for developing septic shock. Alternatively, these determinations may serve to identify women who will have a hemodynamic decompensation among those with clinical chorioamnionitis. However, the relationship between plasma TNF- α concentrations (and other cytokines) and septic shock is complex. It is important to note that TNF- α can also induce tachyphylaxis.

The observations reported herein are important because many cases of maternal death that have been attributed to AFE may in fact have been caused by subclinical infections.^{2;26;124–126} This is particularly likely with maternal deaths following first or second trimester abortions that have been attributed to AFE.^{127;128} These cases have been particularly puzzling because the volume of amniotic fluid in the midtrimester is small and contains little particulate matter. These cases have been poorly documented and based on death certificates or unverified autopsy diagnoses. These are frequently inaccurate because medical records often retain the original diagnoses even when these are not confirmed by autopsy, and also because the histological material in the lungs may be misinterpreted.^{26;129} The recognition that subclinical infections of the amniotic fluid cavity may cause a clinical picture indistinguishable from AFE should lead to earlier diagnosis and treatment of sepsis in these cases, and perhaps an improved outcome.

It is also possible that TNF- α and other inflammatory mediators produced in response to TNF- α may mediate the host responses to AFE, namely, cardiorespiratory failure, myocardial depression, pulmonary edema, and DIC, which are similar to the pathophysiological changes they mediate in septic shock. TNF- α is produced by monocytes and macrophages. Keratin elicits a foreign body giant cell reaction in the body as is frequently observed in ruptured epidermal inclusion cysts, well-differentiated squamous cell carcinomas and pilonidal sinuses.¹³⁰ Keratin is present in the fetal squames that embolize to the lung in AFE. Mucin, which is the component of amniotic fluid debris most commonly identified in the lungs,¹¹⁴ can elicit a histiocytic tissue reaction as in ruptured mucinous cysts of the lip. Meigs¹¹⁵ reported extensive macrophage mobilization and an intense phagocytic response in the lungs of a patient who died of AFE, which caused sudden cardiopulmonary arrest in labor. The author postulated that the intense phagocytic response was to the granular material present in amniotic fluid debris.¹¹⁵ Less dramatic macrophage responses have been reported by others.¹⁰³ Meigs¹¹⁵ suggested that the intensity of the phagocytic response observed in histologic material will depend on the duration of symptoms prior to death because after some time the phagocytes dissipate and migrate to the lymph glands. Further research into this question is warranted.

Meconium in the amniotic fluid, AFE and intra-amniotic infection

Meconium was present in the amniotic fluid of the first patient. This is noteworthy because experimental studies in animals indicate that amniotic fluid containing meconium is more likely to elicit the AFE syndrome than filtered amniotic fluid.^{30;31;131} The traditional interpretation of this is that the particulate matter is responsible for the emboli in the maternal lung. However, we have previously reported that intra-amniotic infection is more common in patients with meconium-stained amniotic fluid, and we have also demonstrated that endotoxin can be detected more frequently in meconium-stained than in clear amniotic fluid.¹³²

Why did women develop cardiovascular collapse and DIC in the postpartum period?

Cardiovascular collapse and DIC may occur any time during the course of infection; yet, in our cases, it occurred in the immediate postpartum period. We have previously reported that trophoblast can deactivate neutrophils and monocytes upon contact.¹³³ Thus, maternal activated neutrophils and monocytes entering the intervillous space can change their biological properties (including the production of reactive oxygen radicals, NADPH oscillations and calcium spikes) after touching the villous trophoblast. Thus, pregnant women carry an “inactivation chamber” for cells of the innate limb of the immune response. We have proposed that this unique immune adaptation evolved to prevent rejection/damage of the placenta, which is 50% foreign. Contact deactivation of neutrophils and monocytes is however transient, because studies of flow cytometry have demonstrated that the phenotype

and metabolic properties of circulating cells is consistent with that of activation. We envision that upon delivery of the placenta, this “inactivation chamber” (the intervillous space of the placenta) is no longer available, and therefore, activated monocytes and neutrophils (because of infection) may lead to septic shock. Further studies are required to determine if most cases of septic shock associated with intra-amniotic infection occur in the postpartum period. We have recently determined the molecular basis for contact deactivation¹³³ and this may open avenues for the treatment of septic shock.

In conclusion, shock, presenting suddenly with cardiopulmonary collapse during labor, delivery or shortly after delivery, has been recognized as a distinct syndrome for many years, and usually is attributed to AFE.^{1;2;6;98;134} We describe two cases in which postpartum shock and DIC occurring was associated with intraamniotic infection. These observations have implications for understanding the spectrum of disease of intrauterine infection during pregnancy and to develop means to identify the patient at risk for cardiovascular collapse and DIC. It is possible that early diagnosis and novel treatments help improve the prognosis of the patient at risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported, in part, by the Intramural Research Program of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NIH, DHHS, by the Wayne State University School of Medicine and the Detroit Medical Center.

Reference List

1. Clark SL. New concepts of amniotic fluid embolism: a review. *Obstet Gynecol Surv* 1990;45:360–368. [PubMed: 2195407]
2. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol* 1995;172:1158–1167. [PubMed: 7726251]
3. Benson MD. Anaphylactoid syndrome of pregnancy. *Am J Obstet Gynecol* 1996;175:749. [PubMed: 8828446]
4. Benson MD, Lindberg RE. Amniotic fluid embolism, anaphylaxis, and tryptase. *Am J Obstet Gynecol* 1996;175:737. [PubMed: 8828443]
5. Meyer JR. Embolia Pulmonar Amnio-Caseosa. *Brazil-Med* 1926;2:301–303.
6. Steiner PE, Lushbaugh CC. Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. *JAMA* 1941;117:1245–1254.
7. Steiner PE, Lushbaugh CC, Frank H. Fatal obstetric shock from pulmonary emboli of amniotic fluid. *Am J Obstet Gynecol* 1949;58:802–805. [PubMed: 18140501]
8. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. *Crit Care Med* 1989;17:489–494. [PubMed: 2721208]
9. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. *Lancet* 1987;1:355–357. [PubMed: 2880163]
10. Schaerf RH, de Campo T, Civetta JM. Hemodynamic alterations and rapid diagnosis in a case of amniotic-fluid embolus. *Anesthesiology* 1977;46:155–157. [PubMed: 835851]
11. Masson RG, Ruggieri J, Siddiqui MM. Amniotic fluid embolism: definitive diagnosis in a survivor. *Am Rev Respir Dis* 1979;120:187–192. [PubMed: 380421]
12. Dolyuniuk M, Orfei E, Vania H, Karlman R, Tomich P. Rapid diagnosis of amniotic fluid embolism. *Obstet Gynecol* 1983;61:28S–30S. [PubMed: 6337361]

13. Duff P, Engelsgerd B, Zingery LW, Huff RW, Montiel MM. Hemodynamic observations in a patient with intrapartum amniotic fluid embolism. *Am J Obstet Gynecol* 1983;146:112–115. [PubMed: 6846416]
14. Clark SL, Montz FJ, Phelan JP. Hemodynamic alterations associated with amniotic fluid embolism: a reappraisal. *Am J Obstet Gynecol* 1985;151:617–621. [PubMed: 3976762]
15. Clark SL. Amniotic fluid embolism. *Clin Perinatol* 1986;13:801–811. [PubMed: 3539452]
16. Clark SL, Cotton DB, Gonik B, Greenspoon J, Phelan JP. Central hemodynamic alterations in amniotic fluid embolism. *Am J Obstet Gynecol* 1988;158:1124–1126. [PubMed: 3369495]
17. Shechtman M, Ziser A, Markovits R, Rozenberg B. Amniotic fluid embolism: early findings of transesophageal echocardiography. *Anesth Analg* 1999;89:1456–1458. [PubMed: 10589627]
18. Stanten RD, Iverson LI, Daugharty TM, Lovett SM, Terry C, Blumenstock E. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. *Obstet Gynecol* 2003;102:496–498. [PubMed: 12962931]
19. James CF, Feinglass NG, Menke DM, Grinton SF, Papadimos TJ. Massive amniotic fluid embolism: diagnosis aided by emergency transesophageal echocardiography. *Int J Obstet Anesth* 2004;13:279–283. [PubMed: 15477062]
20. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. *Am J Obstet Gynecol* 2009;201:445.e1–e13. [PubMed: 19879393]
21. Romero R, Mazor M, Wu YK, Sirtori M, Oyarzun E, Mitchell MD, Hobbins JC. Infection in the pathogenesis of preterm labor. *Semin Perinatol* 1988;12:262–279. [PubMed: 3065940]
22. Romero R, Mazor M, Wu YK, Avila C, Oyarzun E, Mitchell MD. Bacterial endotoxin and tumor necrosis factor stimulate prostaglandin production by human decidua. *Prostaglandins Leukot Essent Fatty Acids* 1989;37:183–186. [PubMed: 2692033]
23. Romero R, Mazor M, Manogue K, Oyarzun E, Cerami A. Human decidua: a source of cachectin-tumor necrosis factor. *Eur J Obstet Gynecol Reprod Biol* 1991;41:123–127. [PubMed: 1936492]
24. Fidel PL Jr, Romero R, Ramirez M, Cutright J, Edwin SS, LaMarche S, Cotton DB, Mitchell MD. Interleukin-1 receptor antagonist (IL-1ra) production by human amnion, chorion, and decidua. *Am J Reprod Immunol* 1994;32:1–7. [PubMed: 7945810]
25. WEINER AE, REID DE. The pathogenesis of amniotic-fluid embolism. III. Coagulant activity of amniotic fluid. *N Engl J Med* 1950;243:597–598. [PubMed: 14780342]
26. Clark SL, Pavlova Z, Greenspoon J, Horenstein J, Phelan JP. Squamous cells in the maternal pulmonary circulation. *Am J Obstet Gynecol* 1986;154:104–106. [PubMed: 2418682]
27. ATTWOOD HD. A HISTOLOGICAL STUDY OF EXPERIMENTAL AMNIOTIC- FLUID AND MECONIUM EMBOLISM IN DOGS. *J Pathol Bacteriol* 1964;88:285–290. [PubMed: 14194990]
28. ATTWOOD HD, DOWNING ES. EXPERIMENTAL AMNIOTIC FLUID AND MECONIUM EMBOLISM. *Surg Gynecol Obstet* 1965;120:255–262. [PubMed: 14257928]
29. Reis RL, Pierce WS, Behrendt DM. Hemodynamic effects of amniotic fluid embolism. *Surg Gynecol Obstet* 1969;129:45–48. [PubMed: 5790701]
30. Hankins GD, Snyder RR, Clark SL, Schwartz L, Patterson WR, Butzin CA. Acute hemodynamic and respiratory effects of amniotic fluid embolism in the pregnant goat model. *Am J Obstet Gynecol* 1993;168:1113–1129. [PubMed: 8475957]
31. Hankins GD, Snyder R, Dinh T, Van Hook J, Clark S, Vandelan A. Documentation of amniotic fluid embolism via lung histopathology. Fact or fiction? *J Reprod Med* 2002;47:1021–1024. [PubMed: 12516321]
32. Stolte L, van KH, Seelen J, Eskes T, Wagatsuma T. Failure to produce the syndrome of amniotic fluid embolism by infusion of amniotic fluid and meconium into monkeys. *Am J Obstet Gynecol* 1967;98:694–697. [PubMed: 4961377]
33. Adamsons K, Mueller-Heubach E, Myers RE. The innocuousness of amniotic fluid infusion in the pregnant rhesus monkey. *Am J Obstet Gynecol* 1971;109:977–984. [PubMed: 4994277]
34. Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism. A case report. *J Reprod Med* 2001;46:926–928. [PubMed: 11725740]

35. Nishio H, Matsui K, Miyazaki T, Tamura A, Iwata M, Suzuki K. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. *Forensic Sci Int* 2002;126:53–56. [PubMed: 11955833]
36. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snyderman DR, Black E, Schwartz JS, Moore R, Johnson BL Jr, Platt R. Epidemiology of sepsis syndrome in 8 academic medical centers. *JAMA* 1997;278:234–240. [PubMed: 9218672]
37. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. *Crit Care Med* 1998;26:2078–2086. [PubMed: 9875924]
38. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303–1310. [PubMed: 11445675]
39. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003;348:1546–1554. [PubMed: 12700374]
40. Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, Opal SM, Glauser M, Parsons P, Fisher CJ Jr, Repine JE. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. *Crit Care Med* 2000;28:232–235. [PubMed: 10667529]
41. Matot I, Sprung CL. Definition of sepsis. *Intensive Care Med* 2001;27(Suppl 1):S3–9. S3–S9. [PubMed: 11307368]
42. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001;344:699–709. [PubMed: 11236773]
43. Czura CJ, Yang H, Amella CA, Tracey KJ. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. *Adv Immunol* 2004;84:181–200. 181–200. [PubMed: 15246253]
44. Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. *Nat Med* 2004;10:124–125. [PubMed: 14760415]
45. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. *Semin Reprod Med* 2007;25:21–39. [PubMed: 17205421]
46. Jalava J, Mantymaa ML, Ekblad U, Toivanen P, Skurnik M, Lassila O, Alanen A. Bacterial 16S rDNA polymerase chain reaction in the detection of intra-amniotic infection. *Br J Obstet Gynaecol* 1996;103:664–669. [PubMed: 8688393]
47. Hitti J, Riley DE, Krohn MA, Hillier SL, Agnew KJ, Krieger JN, Eschenbach DA. Broad-spectrum bacterial rDNA polymerase chain reaction assay for detecting amniotic fluid infection among women in premature labor. *Clin Infect Dis* 1997;24:1228–1232. [PubMed: 9195088]
48. Yoon BH, Romero R, Kim M, Kim EC, Kim T, Park JS, Jun JK. Clinical implications of detection of *Ureaplasma urealyticum* in the amniotic cavity with the polymerase chain reaction. *Am J Obstet Gynecol* 2000;183:1130–1137. [PubMed: 11084554]
49. Yoon BH, Romero R, Lim JH, Shim SS, Hong JS, Shim JY, Jun JK. The clinical significance of detecting *Ureaplasma urealyticum* by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. *Am J Obstet Gynecol* 2003;189:919–924. [PubMed: 14586326]
50. Gardella C, Riley DE, Hitti J, Agnew K, Krieger JN, Eschenbach D. Identification and sequencing of bacterial rDNAs in culture-negative amniotic fluid from women in premature labor. *Am J Perinatol* 2004;21:319–323. [PubMed: 15311367]
51. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, Kim CJ, Erez O, Edwin S, Relman DA. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS One* 2008;3:e3056. [PubMed: 18725970]
52. Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. *J Infect Dis* 1982;145:1–8. [PubMed: 7033397]
53. Ulloa L, Tracey KJ. The “cytokine profile”: a code for sepsis. *Trends Mol Med* 2005;11:56–63. [PubMed: 15694867]
54. Tracey KJ, Cerami A. Metabolic responses to cachectin/TNF. A brief review. *Ann N Y Acad Sci* 1990;587:325–31. 325–331. [PubMed: 2193578]

55. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. *Nature* 1987;330:662–664. [PubMed: 3317066]
56. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. *Annu Rev Cell Biol* 1993;9:317–43. 317–343. [PubMed: 8280464]
57. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. *Annu Rev Med* 1994;45:491–503. 491–503. [PubMed: 8198398]
58. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003;348:138–150. [PubMed: 12519925]
59. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. *N Engl J Med* 1988;318:1481–1486. [PubMed: 2835680]
60. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. *Crit Care Med* 1989;17:975–978. [PubMed: 2791581]
61. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. *JAMA* 1994;271:1836–1843. [PubMed: 8196140]
62. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der AP. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. *Crit Care Med* 2001;29:503–510. [PubMed: 11373411]
63. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. *Cell* 1989;56:731–740. [PubMed: 2647299]
64. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. *J Immunol* 1992;148:2724–2730. [PubMed: 1315357]
65. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. *Shock* 1995;4:89–95. [PubMed: 7496903]
66. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. *Curr Med Chem* 2009;16:3152–3167. [PubMed: 19689289]
67. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. *Nat Rev Rheumatol* 2009;5:578–582. [PubMed: 19798034]
68. Tracey, K. The Acute and Chronic Pathophysiologic Effects of TNF: Mediation of Septic Shock and Wasting (Cachexia). In: Butler, Bruce, editor. *Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine*. New York: Raven Press, Ltd; 2007. p. 255-273.
69. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. *Am J Reprod Immunol* 2007;58:138–149. [PubMed: 17631007]
70. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. *Am J Reprod Immunol* 2008;60:8–16. [PubMed: 18422811]
71. Clark DA. Should anti-TNF-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? *Am J Reprod Immunol* 2009;61:107–112. [PubMed: 19143674]
72. Skomsvoll JF, Wallenius M, Koksvik HS, Rodevand E, Salvesen KA, Spigset O, Kvien TK. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. *Nat Clin Pract Rheumatol* 2007;3:156–164. [PubMed: 17334338]

73. Chaouat G. Comment: Primum non-Nocere. *Am J Reprod Immunol* 2008;60:17–18. [PubMed: 18593433]
74. Berthelot JM, De BM, Goupille P, Solau-Gervais E, Liote F, Goeb V, Azais I, Martin A, Pallot-Prades B, Maugars Y, Mariette X. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. *Joint Bone Spine* 2009;76:28–34. [PubMed: 19059799]
75. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. *J Rheumatol* 2009;36:635–641. [PubMed: 19132789]
76. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD. Shock and tissue injury induced by recombinant human cachectin. *Science* 1986;234:470–474. [PubMed: 3764421]
77. DeForge LE, Nguyen DT, Kunkel SL, Remick DG. Regulation of the pathophysiology of tumor necrosis factor. *J Lab Clin Med* 1990;116:429–438. [PubMed: 2212853]
78. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. *J Infect Dis* 1990;161:982–987. [PubMed: 2109023]
79. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. *Chest* 1993;103:565–575. [PubMed: 8432155]
80. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, Sabo V, Athanassiadis AP, Hobbins JC. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am J Obstet Gynecol* 1989;161:817–824. [PubMed: 2675611]
81. Pisa P, Gennene M, Soder O, Ottenhoff T, Hansson M, Kiessling R. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. *J Infect Dis* 1990;161:988–991. [PubMed: 2324549]
82. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. *J Clin Oncol* 1988;6:344–350. [PubMed: 3339398]
83. Peetre C, Thysell H, Grubb A, Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. *Eur J Haematol* 1988;41:414–419. [PubMed: 2850215]
84. Laham N, Brennecke SP, Bendtzen K, Rice GE. Tumour necrosis factor alpha during human pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. *Eur J Endocrinol* 1994;131:607–614. [PubMed: 7804444]
85. Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I. Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. *Mediators Inflamm* 1998;7:69–72. [PubMed: 9836491]
86. Weiyuan Z, Li W. Study of interleukin-6 and tumor necrosis factor-alpha levels in maternal serum and amniotic fluid of patients with premature rupture of membranes. *J Perinat Med* 1998;26:491–494. [PubMed: 10224608]
87. Nowak M, Oszukowski P, Jaczewski B, Malafiej E, Wierzbicka E, Czichos E, Wilczynski JR, Szpakowski M. Maternal serum cytokines in labor, pregnancy and chorioamnionitis. *Ginekol Pol* 2001;72:1158–1162. [PubMed: 11883229]
88. Gucer F, Balkanli-Kaplan P, Yuksel M, Sayin NC, Yuce MA, Yardim T. Maternal serum levels of tumor necrosis factor-alpha and interleukin-2 receptor in threatened abortion: a comparison with normal and pathologic pregnancies. *Fertil Steril* 2001;76:707–711. [PubMed: 11591402]
89. Serin IS, Ozcelik B, Basbug M, Kilic H, Okur D, Erez R. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. *Eur J Obstet Gynecol Reprod Biol* 2002;100:143–145. [PubMed: 11750953]
90. Bahar AM, Ghalib HW, Moosa RA, Zaki ZM, Thomas C, Nabri OA. Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-alpha and interferon-gamma in preterm labor. *Acta Obstet Gynecol Scand* 2003;82:543–549. [PubMed: 12780425]

91. Muzammil S, Singhal U, Gulati R, Bano I. Serum tumor necrosis factor-alpha in pre eclampsia. *Indian J Physiol Pharmacol* 2005;49:236–240. [PubMed: 16170994]
92. Montagnana M, Lippi G, Albiero A, Salvagno GL, Franchi M, Guidi GC. Serum pro-inflammatory cytokines in physiological and pre-eclamptic pregnancies. *Gynecol Endocrinol* 2008;24:113–116. [PubMed: 18335322]
93. Saarelainen H, Valtonen P, Punnonen K, Laitinen T, Raitakari OT, Juonala M, Heiskanen N, Lyyra-Laitinen T, Viikari JS, Heinonen S. Flow mediated vasodilation and circulating concentrations of high sensitive C-reactive protein, interleukin-6 and tumor necrosis factor-alpha in normal pregnancy--The Cardiovascular Risk in Young Finns Study. *Clin Physiol Funct Imaging* 2009;29:347–352. [PubMed: 19489963]
94. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H. Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. *Hypertens Pregnancy* 2009;28:190–200. [PubMed: 19437229]
95. Chedraui P, Lockwood CJ, Schatz F, Buchwalder LF, Schwager G, Guerrero C, Escobar GS, Hidalgo L. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. *J Matern Fetal Neonatal Med* 2009;22:565–570. [PubMed: 19350449]
96. Valtonen P, Punnonen K, Saarelainen H, Heiskanen N, Raitakari OT, Viikari JS, Lyyra-Laitinen T, Laitinen T, Heinonen S. Maternal serum ADMA is not associated with proinflammatory cytokines or C-reactive protein during normal pregnancy. *Cytokine* 2009;46:216–221. [PubMed: 19268605]
97. Dermitzaki E, Staikou C, Petropoulos G, Rizos D, Siafaka I, Fassoulaki A. A randomized study of maternal serum cytokine levels following cesarean section under general or neuraxial anesthesia. *Int J Obstet Anesth* 2009;18:33–37. [PubMed: 19026531]
98. Steiner PE, Lushbaugh CC. Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. *JAMA* 1941;117:1340–1345.
99. Gross P, Benz E. Pulmonary embolism by amniotic fluid: report of 3 cases with a new diagnostic procedure. *Surg, Gynec & Obst* 1947;85:315–320. [PubMed: 20258687]
100. Hemmings CT. Maternal Pulmonary Embolism by contents of the amniotic fluid. *Am J Obstet Gynecol* 1947;53:303–306. [PubMed: 20286649]
101. Shotton D, Taylor C. Pulmonary embolism by amniotic fluid: a report of a fatal case, together with a review of the literature. *J Obstet Gynecol Br Emp* 1949;56:46–53. [PubMed: 18112328]
102. Jennings E, Stofer B. Pulmonary Emboli Composed of Contents of Amniotic Fluid. *Arch Pathol* 1948;45:616–621.
103. Lushbaugh CC, Steiner PE. Additional observations on maternal pulmonary embolism by amniotic fluid. *Am J Obstet Gynecol* 1942;43:833–838.
104. MALLORY GK, BLACKBURN N, SPARLING HJ, NICKERSON DA. Maternal pulmonary embolism by amniotic fluid; report of three cases and discussion of the literature. *N Engl J Med* 1950;243:583–587. [PubMed: 14780339]
105. Wyatt J, Goldenberg H. Amniotic fluid embolism: reprot of a fatal case. *Arch Pathol* 1948;45:366–370.
106. BOUTON SM Jr, SAUNDERS JR. Pulmonary embolism of amniotic fluid; report of case with review of literature. *Am J Clin Pathol* 1951;21:566–572. [PubMed: 14846760]
107. SLUDER HM, LOCK FR. Sudden maternal death associated with amniotic fluid embolism. *Am J Obstet Gynecol* 1952;64:118–125. [PubMed: 14933522]
108. DENNISS RG, GOLDIE W, POLSON CJ. Amniotic embolism; a report of two fatalities. *J Obstet Gynaecol Br Emp* 1954;61:620–622. [PubMed: 13212491]
109. GRAHAM HK. Amniotic fluid embolism. *Am J Obstet Gynecol* 1955;70:657–659. [PubMed: 13238513]
110. STONE S, KOUCKY R, LELAND HR. A fatal case of amniotic fluid embolism. *Am J Obstet Gynecol* 1955;70:660–662. [PubMed: 13238514]
111. SCOFIELD GF, BEAIRD JB Jr. Fatal embolism by amniotic fluid in the lungs; report of a case. *Am J Clin Pathol* 1957;28:400–404. [PubMed: 13478543]

112. ATTWOOD HD, ROME RM. Amniotic embolism and uterine rupture. *Aust N Z J Obstet Gynaecol* 1963;3:73–77. [PubMed: 13965397]
113. Liban E, Raz S. A clinicopathologic study of fourteen cases of amniotic fluid embolism. *Am J Clin Pathol* 1969;51:477–486. [PubMed: 5774662]
114. Peterson EP, Taylor HB. Amniotic fluid embolism. An analysis of 40 cases. *Obstet Gynecol* 1970;35:787–793. [PubMed: 5441272]
115. Meigs LC. Amniotic fluid embolism. Pulmonary histopathologic findings in a rapidly fatal occurrence of amniotic fluid embolism. *Am J Obstet Gynecol* 1971;111:1069–1074. [PubMed: 5129562]
116. Barrows JJ. A documented case of amniotic fluid embolism presenting as acute fetal distress. *Am J Obstet Gynecol* 1982;143:599–600. [PubMed: 7091232]
117. Mulder JJ. Amniotic fluid embolism: an overview and case report. *Am J Obstet Gynecol* 1985;152:430–435. [PubMed: 4014335]
118. McDougall RJ, Duke GJ. Amniotic fluid embolism syndrome: case report and review. *Anaesth Intensive Care* 1995;23:735–740. [PubMed: 8669613]
119. Martin RW. Amniotic fluid embolism. *Clin Obstet Gynecol* 1996;39:101–106. [PubMed: 8635292]
120. CRON RS, KILKENNY GS, WIRTHWEIN C, EVRARD JR. Amniotic fluid embolism. *Am J Obstet Gynecol* 1952;64:1360–1363. [PubMed: 12996600]
121. MacMillan D. Experimental amniotic fluid infusion. *J Obstet Gynaecol Br Commonw* 1968;75:849–852. [PubMed: 5691715]
122. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. *Curr Opin Crit Care* 2009;15:392–397. [PubMed: 19633546]
123. Li XQ, Cao W, Li T, Zeng AG, Hao LL, Zhang XN, Mei QB. Amlodipine inhibits TNF- α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. *Int Immunopharmacol* 2009;9:1032–1041. [PubMed: 19393774]
124. SHELLEY RJ, DENNISON AD Jr, THOMPSON JV. Pulmonary embolism by amniotic fluid. *Dis Chest* 1959;36:616–623. [PubMed: 14445782]
125. Nichols GP, Raney EH. Postpartum confusion: heart failure or amniotic fluid embolism? *Arch Intern Med* 1966;117:807–812. [PubMed: 5949045]
126. Lumley J, Owen R, Morgan M. Amniotic fluid embolism. A report of three cases. *Anaesthesia* 1979;34:33–36. [PubMed: 426238]
127. Guidotti RJ, Grimes DA, Cates W Jr. Fatal amniotic fluid embolism during legally induced abortion, United States, 1972 to 1978. *Am J Obstet Gynecol* 1981;141:257–261. [PubMed: 7282806]
128. Cromey MG, Taylor PJ, Cumming DC. Probable amniotic fluid embolism after first-trimester pregnancy termination. A case report. *J Reprod Med* 1983;28:209–211. [PubMed: 6682893]
129. THOMPSON WB, BUDD JW. ERRONEOUS DIAGNOSES OF AMNIOTIC FLUID EMBOLISM. *Am J Obstet Gynecol* 1965;91:606–620. [PubMed: 14266205]
130. Schwartz IS, Bello GV, Feigin G, Sherman DH. Maternal vernix caseosa peritonitis following premature rupture of fetal membranes. *JAMA* 1985;254:948–950. [PubMed: 3894706]
131. Petroianu GA, Altmannberger SH, Maleck WH, Assmus HP, Friedberg C, Bergler WF, Rufer R. Meconium and amniotic fluid embolism: effects on coagulation in pregnant mini-pigs. *Crit Care Med* 1999;27:348–355. [PubMed: 10075060]
132. Romero R, Kadar N, Lafreniere D, Durum S, Hobbins JC, Duff GW. Do blood and meconium affect the detection of endotoxin in amniotic fluid with the limulus amoebocyte gel clot assay? *Am J Perinatol* 1987;4:356–359. [PubMed: 3307803]
133. Petty HR, Kindzelskii AL, Espinoza J, Romero R. Trophoblast contact deactivates human neutrophils. *J Immunol* 2006;176:3205–3214. [PubMed: 16493081]
134. Schneider CL. Obstetric shock; some interdependent problems of coagulation. *Obstet Gynecol* 1954;4:273–294. [PubMed: 13194255]